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Excipients represent diverse classes of molecules, small molecules or macromolecules, with versatile structures within a
given class and are from natural, semi-synthetic and synthetic sources. They are essential ingredients in drug products
independently of the route of administration where both traditional and non-traditional uses are present. Beyond their
traditional use as formulation and manufacturing aids, certain excipients exhibit biological effects and thus can be used
either as atypical active pharmaceutical ingredients alone or synergistically with conventional active pharmaceutical
ingredients to affect the overall pharmacokinetics/ pharmacodynamics and therapeutic effect(s) of the co-administered
drug(s). In reference to oral drugs, biological effects of the excipients that contribute to improved drug absorption and
pharmacokinetics include their ability to modulate drug dissolution, intestinal membrane permeability, gut wall
metabolism and efflux pumps. These non-traditional uses of excipients are illustrated in representative case studies
from published literature. From a drug development and regulatory perspective, it is apparent that an appropriate
excipient classification system is considered which is applied to new uses of existing excipients as well as to the
development of novel excipients and segregates biologically active excipients from the larger pool of excipients. This
classification system should be a useful tool to pharmaceutical scientists and its successful implementation and broader
acceptance requires input and ownership from all major stakeholders, that is, the excipient manufacturers, the end
users, excipient forums and discussion groups such as the International Pharmaceutical Excipients Council (IPEC) and
regulatory agencies.
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In order to harvest the maximum therapeutic activity of
the drug molecules, appropriate dosage forms are designed
using various additives called ‘Excipients’ (Rowe et al.
2009). It is due to the use of excipients that the drug can
be delivered to the patients in a presentable form that
meets the targeted dose requirements. Excipients represent
diverse classes with versatile structures and are of natural
or semi-synthetic origin, small molecules and macro-
molecules and represent all states of matter, that is,
gases, liquids, semi-solid and solids. Examples of small* Correspondence: constantinpp@aol.com
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the Creative Commons license, and indicate ifmolecule excipients include, mannitol and dextrose, so-
dium chloride, vitamins such as ascorbic acid (vitamin C)
and α-tocopherol (vitamin E), calcium carbonate and
calcium phosphates (Rowe et al. 2009), whereas macro-
molecular excipients include, polyethylene glycols,
methacrylates, povidone, aluminosilicates and hydrocol-
loids, such as starches, cellulose esters, gums, gelatin,
alginates, carrageenan and pectin (Rowe et al. 2009).
Excipients are manufactured in large quantities often
through continuous processing in dedicated plants and
are available in several grades. Traditionally excipients
are regarded as “inert carriers” (inactives). However,
they may also exert biological activity as modulators of
drug absorption and metabolism or as atypical active
pharmaceutical ingredients.article is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Table 2 Examples of Excipients Inhibiting In Vitro/In Vivo
Metabolic Enzymes and Membrane Transporters (Chen 2008;
Constantinides et al. 2007)
Excipient CYP3A P-gp
C8–C20 fatty acid glycerol and PEG esters:
Cremophor EL and RH40, Solutol HS-15,
Labrasol, Softigen 767, Aconnon E
- +
Sodium Caprate - +
Polysorbates : Tween 80, Tween 20 + +
Sucrose esters : sucrose monolaurate - +
Tocol esters : TPGS - +
PEG 300/400 - +
Triton X-100 - +
Pluronic block copolymer (Pluronic F68) + +
Amphiphilic diblock copolymers (Me-PEG-b-PCL) - +
Peppermint Oil + -
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and are present in marketed oral and parenteral drug
products have been reported in the literature (Strickley
2004; Wasan 2007). Alteration of the permeability of the
drug, however, requires chemical modification of the drug
molecule which often alters its therapeutic activity and is,
therefore, impractical. Non-structural approaches to im-
prove mucosal membrane permeability rely on the use of
permeation enhancers (Aungst 2012), such as lipidic and
polymeric excipients. The toxicity profile and safety of the
particular enhancer need to be rigorously established by
also considering the fact that excipients levels in oral
dosage forms are significantly higher compared to the
levels of the active pharmaceutical ingredients (Whitehead
et al. 2008; Maher et al. 2009). Examples of permeation
enhancers, a use of excipients that is considered non-
traditional, are listed in Table 1 (Aungst 2012; Whitehead
et al. 2008; Maher et al. 2009).
The appropriate selection and use of excipients to de-
liver drugs is dependent on the requirements during
fabrication, desired dissolution and release profile, organo-
leptic characteristics of the formulation, drug stability and
overall physiochemical characteristics. Analyzing the
above selection criteria clearly indicates that some ex-
cipients used with an objective to modify the in-vivo
dissolution and release profile of the drugs can cause sig-
nificant alteration in its pharmacokinetic profile, resulting
in alteration in its pharmacodynamic activity. Further-
more, as indicated in Table 2, certain excipients exhibit
biological activity by inhibiting metabolic enzymes in the
gut wall and intestinal efflux pumps (Constantinides et al.
2007; Chen 2008). If used intentionally, such excipients by
virtue of their ability to increase the drug’s solubilization
capacity in the intestine, metabolic stability and mem-
brane transport may prove to be extremely useful to
improve bioavailability; otherwise it may result in severeTable 1 Intestinal Permeability Enhancers (Aungst 2012;
Whitehead et al. 2008; Maher et al. 2009)
Chemical Class Molecule
Bile Salts Sodium cholate/deoxycholate
Non-ionic surfactants Cremophor EL/RH40, Solutol-HS-15, TPGS,
Tween 80
Ionic surfactants Phospholipids (lecithin)
Stearylamine, cetyl phosphate
Lauroyl- and palmitoyl-carnitine chloride
Sodium lauryl sulfate
Dioctyl sodium sulfosuccinate
Fatty acids/salts Oleic Acid, sodium caprylate, sodium caprate
Glycerides (C8/10) Capmul MCM, Labrasol
Polymers Chitosan, polycarbophil, starch, carrageenan
Other Sodium salicylate, N-methylpiperazinetoxic plasma drug concentration leading to unwanted side
effects. A realization in recent years is also the fact that
some excipients are also used as atypical active pharma-
ceutical ingredients alone or synergistically with other ac-
tive pharmaceutical ingredients (Drakulich 2011; Boddu
et al. 2015). Atypical active pharmaceutical ingredient is
defined as an excipient that is being used as the active
pharmaceutical ingredient in the formulation. Over- the-
counter (OTC) products are examples where one or more
excipients are used as atypical active pharmaceutical in-
gredients in oral, topical, parenteral and ocular dosage
forms (Boddu et al. 2015). The term atypical active
pharmaceutical ingredient is adapted in the present
commentary except in the cited references where the
synonymous short version “atypical active” appears.
Case studies
Although the presently available list of excipients in the
market is unending, the excipients which have shown to
significantly improve the therapeutic efficacy of drugs
are either small molecules or macromolecules and in-
clude lipids, surfactants, oils, cyclodextrins, ion exchange
resins, hydrogels, hydrophobic polymers and other
(Strickley 2004; Wasan 2007; Constantinides et al. 2007;
Chen 2008). In the case of lipid excipients for example,
some of their traditional uses include, drug solvents and
stabilizers, surfactants, antioxidants and vaccine adjuvants.
Non-traditional uses of lipid excipients include membrane
permeability modulators (Table 1), gut wall metabolism
and efflux pump inhibitors (Table 2) as well as atypical
active pharmaceutical ingredients (Constantinides et al.
2007; Chen 2008); Boddu et al. 2015; Constantinides
et al. 2006; Shukla et al. 2011; Chakraborty et al.; 2009).
These traditional and non-traditional functions of lipid
excipients are illustrated in Tables 1 and 2 and in Fig. 1.














Fig. 1 Traditional and Non-Traditional Uses of Lipid Excipients. Non-traditional uses are highlighted
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non-traditionally for the intestinal delivery of peptide
and protein drugs (George et al. 2006). Likewise, thick-
ening agents such as, layered 2:1 phyllosilicates (clay
minerals) have been evaluated for non-traditional uses,
as antimicrobial agents for example (Haydel et al. 2008).
Another example of a non-traditional use, include sur-
face modified nanostructured aluminosilicates (mont-
morillonite) which have recently been employed to
inhibit the absorption of dietary cholesterol in animals
(Gershkovich et al. 2009). Diverse applications of tocol
family of compounds (tocopherols and tocotrienols) and
tocol esters, such as tocopherol succinate and α-tocopherol-
polyethylene glycol 1000-succinate (TPGS) include
their use as drug delivery vehicles, antioxidants and
therapeutic agents (Constantinides et al. 2006). Increased
membrane permeability of low permeable substances has
been successfully demonstrated in the presence of basic
butylated methacrylic polymers (Alasino et al. 2005;
Grube et al. 2008). Various methacrylic polymers
marketed as Eudragit®, beyond their traditional use as
enteric coating and controlled release excipients, haveTable 3 Traditional and Non-Traditional Uses of Minerals in Pharmac
Gershkovich et al.; 2009; Constantinides 2014)
Minerals Traditional Uses as Fu
Kaolin, Montmorillonite (bentonite), Magnesium
Aluminum Silicate, Talc (hydrated magnesium
silicate), Precipitated Calcium Carbonate,
Calcium sulfate, Dibasic Calcium Phosphate,





glidantsalso been investigated as functional excipients in solid
dispersions of poorly soluble drugs to enhance drug
solubilization and physical stability (Six et al. 2004; Qi
et al. 2008). The latter use of these materials is regarded as
non-traditional. The above examples of excipients can be
distinctly segregated from other excipients like fillers,
binders, lubricants, disintegrants, glidants, colors, flavors,
preservatives, antioxidants, plasticizers etc. (Rowe et al.
2009), which are used as manufacturing aids and have in-
significant relation with the in-vivo performance of the
drug. Table 3 illustrates traditional and non-traditional
uses of pharmaceutical excipients as applied to minerals
(Rowe et al. 2009; Boddu et al. 2015; Gershkovich et al.
2009, Constantinides 2014). Detailed information on
non-traditional uses of the various pharmaceutical min-
erals listed in Table 3 including their use as atypical
pharmaceutical ingredients in OTC medications has been
reported elsewhere (Boddu et al. 2015; Gershkovich et al.
2009, Constantinides 2014). There are indeed multiple
uses of a particular class of excipients, such as minerals,
a characteristic that also applies to other classes of
excipients.euticals (Rowe et al. 2009; Boddu et al. 2015; Haydel et al. 2008,





gastric antacids, laxatives, anti-diarrhea agents,
topical OTC medications, antimicrobial agents:
antiviral, antibacterial antifungal, inhibitors of
the absorption of dietary cholesterol
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ucts as well as in dietary supplements has been the
subject of various conferences and workshops and
more recently of a symposium at the 2014 AAPS An-
nual Meeting in San Diego with a theme Excipients as
Atypical Actives in Nutraceuticals and Pharmaceuticals:
Application and Development Considerations (Constanti-
nides 2014). In this latter program talks included, dietary
role of excipients, excipients as inhibitors of the ab-
sorption of dietary cholesterol, development challenges
in the utilization of atypical actives in drug products
and regulatory perspectives surrounding non-traditional
uses of excipients.
In a regulatory note, Chen et al.; (Chen et al. 2013)
reviewed and analyzed pharmacokinetic data on the
use of osmotically active excipients, such as, sorbitol,
mannitol, D-xylose and PEG400 on the bioavailability
and bioequivalence of BCS III drugs that included, raniti-
dine, cimetidine and amoxicillin, and concluded that, “a
better understanding of the dose–response relationship
of an “active” excipient can facilitate its optimal use in
formulations and further provide opportunities of bio-
waivers while ensuring product quality and performance”.
It was pointed out by the authors that “from a regulatory
viewpoint, the importance of recognizing the presence of
an “active” excipient in the formulation cannot be over-
emphasized during the development for both generic
and innovator companies”. They further suggested that
additional mechanistic studies are needed in order to
shed light into the effects of “active” excipients on drug
absorption and bioavailability/bioequivalence (Chen et al.
2013). These findings are certainly relevant to the perspec-
tives and recommendations presented in this commentary






Fig. 2 Interplay between a proposed Excipient Classification System (ECS) a
Excipients Council and API active pharmaceutical ingredientqualification and classification of excipients as discussed
below.
The effect of twenty commonly used excipients on the
oral bioavailability of nalbuphine, a potent opioid anal-
gesic, in rats and humans was investigated and reported
(Wang et al. 2014). The excipients used included, surfac-
tants (Tween 20/40/80, Cremophor EL/RH40, Solutol
HS-15, Pluronic F68 and sodium lauryl sulfate), PEG
400 and PEG2000, as well as preservatives (methyl and
propyl parabens, and sodium benzoate). Improvement in
the oral bioavailability of nalbuphine was correlated to
the ability of these excipients to inhibit the activity of
UDP-glucoronosyltranferase 2B7 activity, the major meta-
bolic enzyme for nalbuphine, with Tween 20 and PEG400
being the most active, alone and in combination (Wang
et al. 2014).
It should also be pointed out that several biomaterials/
excipients used in various drug carriers such as micro-
and nanoparticles and administered by the oral, parenteral
and other routes of administration, are reported to ex-
hibit bioactivities in the body by modulating cellular
and physiological processes, well beyond their primary
role to modify the pharmacokinetics and biodistribu-
tion of the drug (Yeo et al. 2015). These pharmaceutical
excipients include, chitosan and chitosan derivatives,
hyaluronic acid, pluronics, polar lipids such as pegylated
phospholipids and cationic lipids, cyclodextrins and N-(2-
hydroxylpropyl) methacrylamide copolymers (Yeo et al.
2015). Reported bioactivities of these materials which are
either known or newly discovered include, suppression of
pro-inflammatory cytokine production and slight increase
in tumor burdens (Yeo et al. 2015). As discussed by the
authors, understanding the bioactivities of the drug-free












nd major stakeholders. IPEC designates International Pharmaceutical
Constantinides et al. AAPS Open  (2016) 2:3 Page 5 of 6drug product development is very important to optimize
drug product safety and performance.
Recommendations
Though the above facts are well known, a system to
classify excipients on the basis of their in vivo function-
ality and ability to significantly influence the therapeutic
activity of co-formulated drugs or their use as atypical
active pharmaceutical ingredients is still unavailable. This
is particularly important for novel excipients and new uses
of approved excipients. Driving forces behind a new use of
an approved excipient, include, addressing unmet medical
need(s), no product without the excipient, patent pro-
tection and revenues. Understanding excipient effects
(in vitro/in vivo) and development timeline constraints
including toxicity and safety requirements are critical
to the new use of an approved excipient as well to the
use of a novel excipient. The International Pharmaceutical
Excipients Council (IPEC) has been a strong advocate of
the qualification and uses of excipients and authored
many publications and meeting proceedings that deal with
excipient functionality, specifications, characterization,
manufacturing and quality-by-design (QbD) aspects as
well as toxicity and safety aspects especially with novel
excipients (DeMerlis et al. 2009; Moreton 2010; IPEC
Americas website http://www.ipecamericas.org). A clas-
sification which currently exists as indicated in the
Handbook of Pharmaceutical Excipients (Rowe et al.
2009) depends on their role in the dosage form and
manufacturing application like lubricants, glidants, emul-
sifiers, fillers, rate controlling agents, preservatives etc.
However, this classification system (Rowe et al. 2009) is
based on the function of the excipient in the formulation
and dosage form and fails to address non-traditional uses
of biologically “active” excipients as presented in this
commentary. Therefore, it is recommended that a broad
‘Excipient Classification System’ (ECS) be considered and
introduced to segregate the excipients used as formulation
and manufacturing aids from those affecting the absorp-
tion, distribution, metabolism, and elimination (ADME)
and PK/PD properties of the co-administered drugs. This
would help both established and new researchers in the
area to clearly understand the role of excipients, assist in
their judicious selection and interpretation of the effect of
formulation variables on the in vivo performance of the
dosage forms. Furthermore, ECS would be instrumental
for the regulatory bodies to set standards and introduce
appropriate guidelines to control within required limits or
allow minimum variation in use of such excipients in
post approval cases and also recommend submitting of
adequate information/data related to their use in new
drug products. It should also facilitate the approval process
for novel excipients. A suggested system may include for
example, inactive/inert excipients used as formulation andmanufacturing aids versus excipients exhibiting biological
activity, where the latter can be further subdivided in
excipients that modulate the PK/PD of the co-formulated
drug versus excipients which are atypical active pharma-
ceutical ingredients. Properties such as membrane perme-
ability modulation, gut wall metabolism and efflux pump
inhibition can be considered for the excipients that affect
the PK/PD of the co-formulated drug.
Input from all stakeholders, that is, the excipient man-
ufacturers, end users in the biotech and pharmaceutical
industry, the International Pharmaceutical Excipients
Council (IPEC) and regulatory agencies such as the In-
active Ingredient Subcommittee (IIS) of the CDER of
the FDA, is needed before a widely accepted ECS is im-
plemented. Figure 2 illustrates the interplay between
these stakeholders along with the proposed tentative
three classes of excipients for oral drugs.
Conclusion
It is hoped that this commentary on excipients and ECS
recommendation, would stimulate constructive discus-
sion on this important issue of pharmaceutical excipi-
ents before an appropriate ECS becomes a reality. While
this commentary is focused on oral drug products, dis-
cussed excipient considerations and recommendations
can be broadly applied to excipients used in other routes
of administration.
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